Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives. AZD0486 is a novel IgG ...
AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is currently conducting a ...
Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts. This is an ASCO Meeting Abstract from ...
The BiTE targets CD19 on cancerous cells and CD3 on the surface of T-cells. Credit: even_huang via Shutterstock. · Clinical Trials Arena · even_huang via Shutterstock. The above button links to ...
The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch ...
At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486-- a novel CD19xCD3 bispecific T-cell engager -- showed high response rates and encouraging ...
(RTTNews) - AstraZeneca Plc. (AZN.L) said that results from the ECHO Phase III trial showed the company's Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a ...
AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results